coronary heart disease
Conditions
Interventions
Experimental group:Hetastarch was used as an medium during OCT to guide PCI during OCT
Control group:Contrast was used as an medium during OCT to guide PCI during OCT
Sponsors
The PLA Northern Theater Command General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Subjects >= 18 years old; 2. Subjects must have evidence of myocardial ischemia suitable for elective PCI; 3. Subjects must meet at least three or more items to be identified as CI-AKI high-risk patients: (1) Preoperative estimated glomerular filtration rate eGFR=(30-60) ml/min/1.73m^2; (2) Over 70 years old; (3) Diabetic patients; (4) Application of intra-aortic balloon counterpulsation (IABP); (5) Previous cardiogenic shock; previous cardiac arrest; (6) Anemia (adult male Hb = 70%, or multi-vessel disease, non-target vessel stenosis 1 month; 5. Voluntarily sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. The subject's age is less than 18 years old; 2. Subjects have no evidence of myocardial ischemia undergoing elective PCI; 3. Subjects do not meet the definition of CI-AKI high-risk patients; 4. Preoperative estimated glomerular filtration rate eGFR = 70%, no revascularization; 9. Patients who only use drug balloons; 10. Patients with severe heart failure: patients with ejection fraction (EF) < 35% or NYHA heart function class IV; 11. Hemodynamic instability: KILLIP III, IV patients; 12. Severe anemia: hemoglobin < 60 g/L; 13. Platelet count < 100 x 10^9/L; 14. Patients with intracranial hemorrhage (within 1 month) or major organ hemorrhage or recent surgery for gastrointestinal tumors; 15. Patients with oliguria or anuria (oliguria: urine output less than 400 ml in 24 hours; anuria: urine output less than 100ml in 24 hours); 16. Patients receiving dialysis treatment; 17. Patients who are allergic to hydroxyethyl starch or contrast agents; 18. Pregnant patients; 19. The patient has no willingness for PCI treatment; 20. Combined with other contraindications for coronary intervention; 21. Any situation where informed consent cannot be obtained or the researcher considers it inappropriate to participate in this study; 22. Participate in other ongoing clinical research (except for patients who obtain the primary clinical endpoint).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum creatinine; | — |
Countries
China
Contacts
Public ContactWang Xiaozeng
The PLA Northern Theater Command General Hospital
Outcome results
None listed